Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00714116 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
A Phase 1 study of Lupus Erythematosus, Systemic, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 6
- Study locations
NCT00714116: Completed Phase 1 study of Lupus Erythematosus, Systemic, sponsored by Pfizer.
NCT00714116 is a Phase 1 study of Lupus Erythematosus, Systemic that has completed, run by Pfizer. The registered enrollment target is 30 participants, below the 202-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (85% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00714116, a Phase 1 study of Lupus Erythematosus, Systemic, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
Conditions Studied
Interventions
- DRUG SBI-087
Study Locations (6)
Florida
- Arthritis & Rheumatology Care Center - South Miami
- Miami Research Associates - South Miami
- MRA Clinical Research - South Miami
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Texas
- Metroplex Clinical Research Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
What the finished NCT00714116 record still lists
NCT00714116 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 202-participant average among 29 other Lupus Erythematosus, Systemic trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Lupus Erythematosus, Systemic appearing as the primary indexed condition, and to 1 intervention - of which SBI-087 is the first listed.
NCT00714116 lists 6 locations in 4 states (Florida, North Carolina, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT00714116 about?
NCT00714116 is a clinical study titled "Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus". The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SBI-087 in subjects with Systemic Lupus Erythematosus (SLE).
What is the current status of trial NCT00714116?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2009-03. Estimated completion is 2012-09.
What conditions does trial NCT00714116 study?
This clinical trial studies the following conditions: Lupus Erythematosus, Systemic.
What interventions are being tested in trial NCT00714116?
The interventions under investigation include: SBI-087 (DRUG).
Who is sponsoring clinical trial NCT00714116?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00714116 being conducted?
This trial has 6 study locations across Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Erythematosus, Systemic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00714116's enrollment target sits among peer trials
30 25th of 29 higher than 4 of 29 other Lupus Erythematosus, Systemic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Erythematosus, Systemic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Anti-CD20 in Systemic Lupus Erythematosus
COMPLETED · Phase 1
-
Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis
COMPLETED · Phase 1
-
Phase Ib Study of SC Milatuzumab in SLE
COMPLETED · Phase 1
-
Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia